Sanofi and Regeneron announce positive atopic dermatitis data for Dupixent

Sanofi and Regeneron have announced the publication of positive new clinical trial data supporting their investigational atopic dermatitis therapy Dupixent.

Results from two placebo-controlled phase III studies have been published in the New England Journal of Medicine showing the safety and efficacy of Dupixent among adult patients with inadequately controlled moderate to severe atopic dermatitis.

Both studies met their primary endpoints, showing the drug's positive impact on minimising the extent and severity of the disease, while both also met key secondary endpoints measuring itch reduction, improvement in patient-reported anxiety and depression symptoms, and certain quality of life measures.

Dupixent works by inhibiting signalling of IL-4 and IL-13, two key cytokines required for the type 2 immune response, which is believed to be a major driver in atopic dermatitis and in certain atopic or allergic diseases.

The drug is also being evaluated in ongoing clinical trials for asthma and nasal polyposis.

Study lead author Dr Eric Simpson, of Oregon Health and Science University, said: "These results support the growing body of evidence for Dupixent as a potential new treatment option for patients with moderate-to-severe atopic dermatitis who are struggling to control their disease."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.